Burden of Asbestos-Disease Compensation
First written in FY2017-Q1. 14 of 27 entries say "Mitigated", first in FY2018-Q1. Latest entry: FY2026.
0 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Although the cost burden from compensation and condolence payments under the Company's regulations in relation to asbestos-related health damage is limited, it may continue in the future. In addition, the Company faces lawsuits seeking damages in relation to health damage, which may affect the performance and financial condition of the Group.」
No asbestos-related illness compensation was recorded in the current fiscal year, but the possibility that the compensation burden will continue and the litigation risk remain disclosed. - FY2026-H1MitigatedAnnual report
「Current consolidated interim accounting period (1 April 2025 to 30 September 2025) No applicable items.」
No asbestos-related illness compensation was recorded in the current interim period, and the ¥42 million in compensation recorded in the same period of the previous year was not recorded in the current period. - FY2025MaterialisedAnnual report
「Asbestos-related illness compensation － ※7 42」
Although no amount was recorded in the previous year, ¥42 million in asbestos-related illness compensation was recorded as an extraordinary loss in the current consolidated fiscal year. The possibility of litigation and the compensation burden also continue. - FY2025-H1MaterialisedAnnual report
「These are compensation payments to former employees of the Company or its affiliates who were certified as having an occupational illness caused by asbestos, and to their bereaved families.」
Although there was no applicable item in the same period of the previous year, ¥42 million in asbestos-related illness compensation was recorded as an extraordinary loss in the interim period. - FY2024-Q2MitigatedAnnual report
「Payments of asbestos-related illness compensation △ 12 －」
No payments of asbestos-related illness compensation were made during the cumulative second quarter, reducing the compensation burden from ¥12 million in the same period of the previous year. - FY2023MitigatedAnnual report
「Although the cost burden from compensation and condolence payments under the Company's regulations is limited, it may continue in the future. In addition, the Company faces lawsuits seeking damages in relation to health damage, which may affect the performance and financial condition of the Group.」
No asbestos-related illness compensation was recorded as an extraordinary loss in the current fiscal year, and payments decreased to ¥12 million, while the compensation burden and the possibility of litigation continue. - FY2023-Q3MitigatedAnnual report
「Cumulative third quarter of the consolidated fiscal period (1 April 2022 to 31 December 2022) No applicable items.」
No asbestos-related illness compensation was recorded as an extraordinary loss in the cumulative third quarter, and the burden decreased from ¥19 million in the same period of the previous year. - FY2023-Q2MitigatedAnnual report
「Cumulative second quarter of the consolidated interim period (1 April 2022 to 30 September 2022) No applicable items.」
No asbestos-related illness compensation was recorded as an extraordinary loss in the cumulative second quarter, and payments decreased from ¥20 million in the same period of the previous year to ¥12 million. - FY2022MitigatedAnnual report
「Asbestos-related illness compensation ※3 54 ※3 31」
Asbestos-related illness compensation decreased from ¥54 million in the previous year to ¥31 million. Payments through operating activities also decreased from ¥84 million in the previous year to ¥39 million, but the compensation burden continues. - FY2022-Q3MitigatedAnnual report
「Asbestos-related illness compensation ※ 34 ※ 19」
Asbestos-related illness compensation decreased from ¥34 million in the same period of the previous year to ¥19 million, reducing the compensation burden, but costs were still incurred in the current fiscal year. - FY2022-Q2MitigatedAnnual report
「Asbestos-related illness compensation ※2 20 Asbestos-related illness compensation ※2 19」
Asbestos-related illness compensation decreased slightly from ¥20 million in the cumulative period of the previous year to ¥19 million, and payments also decreased from ¥70 million in the same period of the previous year to ¥20 million. However, the compensation burden itself continues. - FY2022-Q1MitigatedAnnual report
「Asbestos-related illness compensation ※ 20 －」
The disclosure states that, although ¥20 million in asbestos-related illness compensation was recorded in the same period of the previous year, there was no applicable item in the first quarter. - FY2021WorsenedAnnual report
「Asbestos-related illness compensation 50 54」
Asbestos-related illness compensation increased from ¥50 million in the previous fiscal year to ¥54 million in the current fiscal year, while payments through operating activities totaled ¥84 million, indicating that the compensation burden continues. - FY2021-Q3WorsenedAnnual report
「Asbestos-related illness compensation － ※ 34」
The Company recorded ¥34 million in asbestos-related illness compensation as an extraordinary loss in the cumulative third quarter, increasing the compensation burden from no amount recorded in the cumulative third quarter of the previous fiscal year and ¥20 million in the previous quarter. - FY2021-Q2Compensation continues to be recorded; payments increaseAnnual report
「Asbestos-related illness compensation － ※2 20 Payments of asbestos-related illness compensation △ 55 △ 70」
The Company recorded ¥20 million in asbestos-related illness compensation as an extraordinary loss, and payments also increased from ¥55 million in the same period of the previous year to ¥70 million. The compensation burden continues. - FY2021-Q1MaterialisedAnnual report
「Asbestos-related illness compensation － ※ 20」
Although no amount was recorded in the same period of the previous year, ¥20 million in asbestos-related illness compensation was recorded as an extraordinary loss in the first quarter, and compensation costs were incurred again. - FY2020-Q2No compensation recorded; payments continueAnnual report
「Cumulative second quarter of the consolidated interim period (1 April 2019 to 30 September 2019) No applicable items. Payments of asbestos-related illness compensation △ 10 △ 55」
Although no asbestos-related illness compensation was recorded as an extraordinary loss in the first half, cash payments of ¥55 million were made, and the compensation burden continues. - FY2020-Q1MitigatedAnnual report
「Asbestos-related illness compensation ※ 10 －」
The Company had recorded ¥10 million in asbestos-related illness compensation in the same period of the previous year, but had no such item in the first quarter, and no compensation costs were incurred during the quarter. - FY2019-Q3MitigatedAnnual report
「Asbestos-related illness compensation ※2 64 ※2 10」
Asbestos-related illness compensation decreased from ¥64 million in the same period of the previous year to ¥10 million. However, the compensation burden itself continues. - FY2019-Q2MitigatedAnnual report
「Asbestos-related illness compensation ※2 15 ※2 10」
Asbestos-related illness compensation decreased from ¥15 million in the same period of the previous year to ¥10 million. However, compensation costs themselves continue to be incurred. - FY2018-Q3WorsenedAnnual report
「Asbestos-related illness compensation ※ 30 ※ 64」
Asbestos-related illness compensation increased from ¥30 million in the same period of the previous year to ¥64 million in the cumulative third quarter, indicating that the compensation burden has expanded. - FY2018-Q2MitigatedAnnual report
「Asbestos-related illness compensation ※2 30 ※2 15」
Asbestos-related illness compensation decreased from ¥30 million in the same period of the previous year to ¥15 million, and compensation payments also decreased from ¥45 million in the same period of the previous year to ¥10 million. However, compensation costs themselves continue to be incurred. - FY2018-Q1MitigatedAnnual report
「Asbestos-related illness compensation ※ 30 ※ 10」
Asbestos-related illness compensation decreased from ¥30 million in the same period of the previous year to ¥10 million in the current quarter, but compensation costs continue to be incurred. - FY2017RestatedAnnual report
「Although the cost burden from compensation and condolence payments under the Company's regulations is limited, it may continue in the future. In addition, if the Company faces lawsuits seeking damages or other claims, the performance and financial condition of the Group may be affected.」
The disclosure states that the burden of compensation and other payments may continue, and the Company recorded ¥30 million in asbestos-related illness compensation on a consolidated basis in the current fiscal year. - FY2017-Q3RestatedAnnual report
「These are compensation payments to former employees of the Company or its affiliates who were certified as having an occupational illness caused by asbestos, and to their bereaved families.」
The Company also recorded ¥30 million in asbestos-related illness compensation as an extraordinary loss for the cumulative third quarter. - FY2017-Q2RestatedAnnual report
「Asbestos-related illness compensation」
The Company recorded ¥30 million in asbestos-related illness compensation as an extraordinary loss and paid ¥45 million through cash flows from operating activities. - FY2017-Q1MaterialisedAnnual report
「These are compensation payments to former employees of the Company or its affiliates who were certified as having an occupational illness caused by asbestos, and to their bereaved families.」
The Company recorded ¥30 million in asbestos-related illness compensation as an extraordinary loss for the quarter, indicating that compensation costs are being incurred.